ArticleCell death discovery2025
SERPINB7 maintains skin barrier by regulating protein O-GalNAc glycosylation.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Deep learning-driven discovery of anti-metastatic phytochemicals targeting MMP-1 in breast cancer via advanced contrastive learning and structural attention.Molecular diversity · 2026Article
- Microglia Mitochondrial Metabolism in Neurological Diseases.Molecular neurobiology · 2026Review
- Molecular insights into nagashima-type palmoplantar keratoderma: SERPINB7 mutation spectrum and mechanistic perspectives.Frontiers in molecular biosciences · 2026Review
- Integrated bioinformatics analysis reveals convergent molecular signatures associated with SERPINB7 and SERPINA12 deficiency.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The skin barrier is crucial for protecting against environmental challenges, preventing water loss, and regulating immune responses. This study aims to investigate the roles and mechanisms of SERPINB7 in skin barrier maintenance. We found that SERPINB7 deficiency disrupts tight junctions of keratinocytes in vitro, and specific knockout of Serpinb7 in keratinocytes impairs skin barrier function in vivo. SERPINB7 deficiency leads to reduced expression of O-GalNAc regulatory proteins and structural abnormalities in the Golgi apparatus, ultimately impairing protein O-GalNAc glycosylation. Legumain acts as a critical mediator in the maintenance of normal biological functions and O-GalNAc glycosylation regulated by SERPINB7. O-GalNAc inhibition exhibits biological effects analogous to those induced by SERPINB7 deficiency, leading to weakened tight junctions, reduced cell adhesion, and compromised skin barrier integrity in keratinocytes and mouse skin, respectively. Consequently, O-GalNAc deficiency exacerbates inflammatory skin diseases such as psoriasis and atopic dermatitis. Mechanistically, O-GalNAc deficiency primarily affects the glycosylation of calcium-related and cell adhesion-related proteins, disrupting calcium signaling and compromising cell adhesion, ultimately leading to skin barrier dysfunction. In summary, this study demonstrates that SERPINB7 maintains skin barrier through protein O-GalNAc glycosylation. These findings not only deepen our understanding of skin barrier biology but also provide new insights for developing therapeutic strategies for skin barrier-related diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.